Abstract
Bone grows then constantly renews itself during adulthood through the succession of cycles of formation by osteoblasts and resorption by osteoclasts. This is a costly process in terms of energy that needs to be coordinated with the amount of available resources, suggesting that bone and appetite and/or energy metabolisms could share common regulator(s). Searching for such molecule(s) identified leptin as a major inhibitor of bone mass accrual that uses central relays to fulfill this function. One of them involves a brain serotonin-dependent regulation of the sympathetic tone, which acts as an inhibitor of bone formation via CREB and the molecular clock and as a positive regulator of bone resorption through an ATF4-Rankl mechanism that takes place in osteoblasts. In contrast, the second mediator of leptin central effect on bone mass accrual, CART, inhibits bone resorption. This chapter details the molecular bases and biological relevance of this regulation of bone mass accrual by leptin.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kronenberg HM. Developmental regulation of the growth plate. Nature. 2003;423(6937):332–6.
Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2(4):389–406.
Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501–4.
Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504–8.
Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature. 2012;481(7381):314–20.
Denver RJ, Bonett RM, Boorse GC. Evolution of leptin structure and function. Neuroendocrinology. 2011;94(1):21–38.
Holbrook TL, Barrett-Connor E. The association of lifetime weight and weight control patterns with bone mineral density in an adult community. Bone Miner. 1993;20(2):141–9. Epub 1993/02/01.
Legroux-Gerot I, Vignau J, Collier F, Cortet B. Bone loss associated with anorexia nervosa. Joint Bone Spine. 2005;72(6):489–95. Epub 2005/10/26.
Legroux-Gerot I, Vignau J, D’Herbomez M, Collier F, Marchandise X, Duquesnoy B, et al. Evaluation of bone loss and its mechanisms in anorexia nervosa. Calcif Tissue Int. 2007;81(3):174–82. Epub 2007/08/02.
Misra M, Klibanski A. Bone health in anorexia nervosa. Curr Opin Endocrinol Diabetes Obes. 2011;18(6):376–82. doi:10.1097/MED.0b013e32834b4bdc.
Riggs BL, Khosla S, Melton 3rd LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763–73.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207.
Friedman JM. Obesity in the new millennium. Nature. 2000;404:632–4.
Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395(6704):763–70.
Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996;87(3):377–89.
Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor OB-R. Cell. 1995;83(7):1263–71.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.
Ahima RS. Body fat, leptin, and hypothalamic amenorrhea. N Engl J Med. 2004;351(10):959–62.
Baldock PA, Sainsbury A, Allison S, Lin EJ, Couzens M, Boey D, et al. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res. 2005;20(10):1851–7.
Vaira S, Yang C, McCoy A, Keys K, Xue S, Weinstein EJ, et al. Creation and preliminary characterization of a leptin knockout rat. Endocrinology. 2012;153(11):5622–8. Epub 2012/09/06.
Solomon G, Atkins A, Shahar R, Gertler A, Monsonego-Ornan E. Effect of peripherally administered leptin antagonist on whole body metabolism and bone microarchitecture and biomechanical properties in the mouse. Am J Physiol Endocrinol Metab. 2014;306(1):E14–27. Epub 2013/10/31.
Ahima RS, Kelly J, Elmquist JK, Flier JS. Distinct physiologic and neuronal responses to decreased leptin and mild hyperleptinemia. Endocrinology. 1999;140(11):4923–31. Epub 1999/10/28.
Reid IR. Glucocorticoid osteoporosis–mechanisms and management. Eur J Endocrinol. 1997;137(3):209–17. Epub 1997/10/23.
Reid IR. Steroid-induced osteoporosis. Osteoporos Int. 1997;7 Suppl 3:S213–6. Epub 1997/01/01.
Suva LJ, Gaddy D, Perrien DS, Thomas RL, Findlay DM. Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep. 2005;3(2):46–51. Epub 2005/07/23.
Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K, Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology. 2006;147(7):3196–202.
Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, et al. Life without white fat: a transgenic mouse. Genes Dev. 1998;12(20):3168–81. Epub 1998/10/24.
Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U S A. 2004;101(9):3258–63.
Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996;12(3):318–20.
Shi Y, Yadav VK, Suda N, Liu XS, Guo XE, Myers Jr MG, et al. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A. 2008;105:20529.
Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. Peptides. 2007;28(5):1012–9. Epub 2007/03/10.
Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, et al. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res. 2006;21(10):1591–9.
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–17.
Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, et al. Central control of bone remodeling by neuromedin U. Nat Med. 2007;13:1234.
Bjorbak C, Lavery HJ, Bates SH, Olson RK, Davis SM, Flier JS, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 2000;275(51):40649–57.
Bjornholm M, Munzberg H, Leshan RL, Villanueva EC, Bates SH, Louis GW, et al. Mice lacking inhibitory leptin receptor signals are lean with normal endocrine function. J Clin Invest. 2007;117(5):1354–60.
Könner AC, Brüning Jens C. Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 2012;16(2):144–52.
Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566–81.
Motyl KJ, Rosen CJ. Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie. 2012;94(10):2089–96.
Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92(1–3):73–8.
Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175(2):405–15.
Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457–62.
Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976–89.
Balthasar N, Coppari R, McMinn J, Liu SM, Lee CE, Tang V, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron. 2004;42(6):983–91.
Oury F, Karsenty G. Towards a serotonin-dependent leptin roadmap in the brain. Trends Endocrinol Metab. 2011;22(9):382–7. Epub 2011/05/24.
Ducy P, Karsenty G. The two faces of serotonin in bone biology. J Cell Biol. 2010;191(1):7–13. Epub 2010/10/06.
Hay-Schmidt A, Helboe L, Larsen PJ. Leptin receptor immunoreactivity is present in ascending serotonergic and catecholaminergic neurons of the rat. Neuroendocrinology. 2001;73(4):215–26. Epub 2001/05/08.
Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM, et al. Leptin targets in the mouse brain. J Comp Neurol. 2009;514(5):518–32. Epub 2009/04/08.
Collin M, Håkansson-Ovesjö M-L, Misane I, Ögren SO, Meister B. Decreased 5-HT transporter mRNA in neurons of the dorsal raphe nucleus and behavioral depression in the obese leptin-deficient ob/ob mouse. Mol Brain Res. 2000;81(1–2):51–61.
Heath MJ, Hen R. Serotonin receptors. Genetic insights into serotonin function. Curr Biol. 1995;5(9):997–9. Epub 1995/09/01.
Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–66. Epub 2009/07/28.
Flomen R, Knight J, Sham P, Kerwin R, Makoff A. Evidence that RNA editing modulates splice site selection in the 5‐HT2C receptor gene. Nucleic Acids Res. 2004;32(7):2113–22.
Drago A, Serretti A. Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(5):601–37.
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387(6630):303–8.
Oury F, Yadav VK, Wang Y, Zhou B, Liu XS, Guo XE, et al. CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev. 2010;24(20):2330–42. Epub 2010/10/19.
Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia. 1973;9(4):294–8.
Bray GA, York DA. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res. 1998;53:95–117.
Kajimura D, Hinoi E, Ferron M, Kode A, Riley KJ, Zhou B, et al. Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual. J Exp Med. 2011;208(4):841–51. Epub 2011/03/30.
Bonnet N, Benhamou CL, Beaupied H, Laroche N, Vico L, Dolleans E, et al. Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats. J Appl Physiol. 2007;102(4):1502–9.
Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada MN, Richard O, et al. Severe bone alterations under β2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone. 2005;37(5):622–33.
Kondo H, Togari A. Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int. 2011;88(1):23–32.
Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther. 2006;318(3):1118–27.
Bonnet N, Benhamou CL, Malaval L, Goncalves C, Vico L, Eder V, et al. Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol. 2008;217(3):819–27.
Thim L, Kristensen P, Larsen PJ, Wulff BS. CART, a new anorectic peptide. Int J Biochem Cell Biol. 1998;30(12):1281–4.
Thim L, Kristensen P, Nielsen PF, Wulff BS, Clausen JT. Tissue-specific processing of cocaine- and amphetamine-regulated transcript peptides in the rat. Proc Natl Acad Sci. 1999;96(6):2722–7.
Wierup N, Kuhar M, Nilsson BO, Mulder H, Ekblad E, Sundler F. Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development. J Histochem Cytochem. 2004;52(2):169–77.
Vrang N, Kristensen P, Tang-Christensen M, Larsen PJ. Effects of leptin on arcuate pro-opiomelanocortin and cocaine-amphetamine-regulated transcript expression are independent of circulating levels of corticosterone. J Neuroendocrinol. 2002;14(11):880–6.
Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 1998;393(6680):72–6.
Elias CF, Lee C, Kelly J, Aschkenasi C, Ahima RS, Couceyro PR, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron. 1998;21(6):1375–85.
Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–20.
Mounzih K, Lu R, Chehab FF. Leptin treatment rescues the sterility of genetically obese ob/ob males. Endocrinology. 1997;138(3):1190–3.
Pierroz D, Baldock PA, Bouxsein ML, Ferrari S. Low cortical bone mass in mice lacking beta 1 and beta 2 adrenergic recptors is associated with low bone formation and circulating IGF-1. J Bone Miner Res. 2006;21 Suppl 1:S26 (Abstract no 1091).
Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V, et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron. 2006;49(2):191–203.
Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ. Regulation of adenylyl cyclase-coupled beta-adrenergic receptors. Annu Rev Cell Biol. 1988;4:405–28.
Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825–37.
Kode A, Mosialou I, Silva BC, Rached MT, Zhou B, Wang J, et al. FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J Clin Invest. 2012;122(10):3490–503. Epub 2012/09/05.
Russell JE, Simmons DJ, Huber B, Roos BA. Meal timing as a zeitgeber for skeletal deoxyribonucleic acid and collagen synthesis rhythms. Endocrinology. 1983;113(6):2035–42.
Nielsen HK. Circadian and circatrigintan changes in osteoblastic activity assessed by serum osteocalcin. Physiological and methodological aspects. Dan Med Bull. 1994;41(2):216–27. Epub 1994/04/01.
Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11(4):281–94. Epub 2000/08/06.
Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell. 2005;122(5):803–15.
Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140(4):1630–8.
Gordeladze JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825–36.
Kim GS, Hong JS, Kim SW, Koh JM, An CS, Choi JY, et al. Leptin induces apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal cells. J Biol Chem. 2003;278(24):21920–9.
Scheller EL, Leinninger GM, Hankenson KD, Myers JMG, Krebsbach PH. Ectopic expression of Col2.3 and Col3.6 promoters in the brain and association with leptin signaling. Cells Tissues Organs. 2011;194(2–4):268–73.
Dacquin R, Starbuck M, Schinke T, Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn. 2002;224(2):245–51.
Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638–49.
Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2004;117(3):387–98.
Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 2006;4(6):441–51.
Iwamoto I, Douchi T, Kosha S, Murakami M, Fujino T, Nagata Y. Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women. Acta Obstet Gynecol Scand. 2000;79(12):1060–4.
Sato M, Takeda N, Sarui H, Takami R, Takami K, Hayashi M, et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab. 2001;86(11):5273–6.
Blum M, Harris SS, Must A, Naumova EN, Phillips SM, Rand WM, et al. Leptin, body composition and bone mineral density in premenopausal women. Calcif Tissue Int. 2003;73(1):27–32. Epub 2003/09/26.
Rauch F, Blum WF, Klein K, Allolio B, Schonau E. Does leptin have an effect on bone in adult women? Calcif Tissue Int. 1998;63(6):453–5. Epub 1998/11/18.
Martini G, Valenti R, Giovani S, Franci B, Campagna S, Nuti R. Influence of insulin-like growth factor-1 and leptin on bone mass in healthy postmenopausal women. Bone. 2001;28(1):113–7.
Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348(9021):159–61.
Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte Jr D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996;2(5):589–93. Epub 1996/05/01.
Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879–84. Epub 1999/09/16.
Simha V, Zerwekh JE, Sakhaee K, Garg A. Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy. J Clin Endocrinol Metabol. 2002;87(11):4942–5.
Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 1998;20(2):111–2.
Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA. 2004;292(11):1326–32.
Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, et al. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone. 2007;40(5):1209–16.
Pasco JA, Henry MJ, Nicholson GC, Schneider HG, Kotowicz MA. Beta-blockers reduce bone resorption marker in early postmenopausal women. Ann Hum Biol. 2005;32(6):738–45.
Turker S, Karatosun V, Gunal I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res. 2006;443:73–4.
Wiens M, Etminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med. 2006;260(4):350–62.
Kurvers HA. Reflex sympathetic dystrophy: facts and hypotheses. Vasc Med. 1998;3(3):207–14.
Patel MS, Elefteriou F. The new field of neuroskeletal biology. Calcif Tissue Int. 2007;80(5):337–47.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ducy, P., Kousteni, S. (2015). Leptin and Bone. In: Dagogo-Jack, MD, S. (eds) Leptin. Springer, Cham. https://doi.org/10.1007/978-3-319-09915-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-09915-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09914-9
Online ISBN: 978-3-319-09915-6
eBook Packages: MedicineMedicine (R0)